Hyperliquid Strategies Inc (PURR) — SEC Filings
Hyperliquid Strategies Inc (PURR) — 4 SEC filings. Latest: 424B3 (May 8, 2026). Includes 1 424B3, 1 10-Q, 1 8-K.
View Hyperliquid Strategies Inc on SEC EDGAR
Overview
Hyperliquid Strategies Inc (PURR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Dec 8, 2025: Hyperliquid Strategies Inc (PURR) reported a net loss of $1,212,921 for the period from its inception on July 2, 2025, through September 30, 2025, with basic and diluted net loss per share at $13,183.92. The company generated no revenues during this period, with all activities related to its formati
Sentiment Summary
Across 4 filings, the sentiment breakdown is: 2 neutral, 2 mixed. The dominant filing sentiment for Hyperliquid Strategies Inc is neutral.
Filing Type Overview
Hyperliquid Strategies Inc (PURR) has filed 1 424B3, 1 10-Q, 1 8-K, 1 S-1 with the SEC between Oct 2025 to May 2026.
Filings by Year
Recent SEC Filings (4)
| Date | Form | Description | Risk |
|---|---|---|---|
| May 8, 2026 | 424B3 | 424B3 Filing | |
| Dec 8, 2025 | 10-Q | Hyperliquid Posts $1.2M Loss Pre-Merger, Secures $1B Equity Line | high |
| Dec 3, 2025 | 8-K | Hyperliquid Strategies Acquires 09 Crypto Assets | medium |
| Oct 22, 2025 | S-1 | Hyperliquid to Raise $1B via Chardan Equity Facility Post-Merger | high |
Risk Profile
Risk Assessment: Of PURR's 3 recent filings, 2 were flagged as high-risk, 1 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$1,212,921 |
| EPS | -$13,183.92 |
| Debt-to-Equity | N/A |
| Cash Position | $0 |
| Operating Margin | N/A |
| Total Assets | $0 |
| Total Debt | $1,212,921 |
Key Executives
- David Schamis
- Alan I. Annex, Esq.
- Jason T. Simon, Esq.
Industry Context
Hyperliquid Strategies Inc. operates in a rapidly evolving digital asset and biotechnology landscape. The company's strategy appears to involve leveraging digital assets (HYPE tokens) in conjunction with biotechnology operations post-business combination. This dual focus places it at the intersection of highly volatile technology markets and the capital-intensive, R&D-driven biotech sector.
Top Tags
Business Combination (2) · Cryptocurrency Exposure (1) · Going Concern (1) · Equity Financing (1) · Pre-Revenue (1) · High Volatility (1) · SPAC-like (1) · acquisition (1) · m-a (1) · corporate-action (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $1.21M | Incurred from inception (July 2, 2025) through September 30, 2025, reflecting pre-operational phase. |
| Net Loss Per Share | $13,183.92 | Basic and diluted net loss per share for the initial operating period. |
| Equity Purchase Agreement | $1.00B | Amount Chardan Capital Markets LLC agreed to purchase in common stock, providing significant post-merger capital. |
| Revenue | 0 | No revenues generated from inception through September 30, 2025, as company was in formation. |
| Shares Outstanding | 127,025,563 | As of December 5, 2025, indicating post-merger share count. |
| Total Current Liabilities | $1,212,921 | As of September 30, 2025, primarily accounts payable and related party debt. |
| Maximum aggregate gross proceeds | $1.0B | Expected from the committed equity facility with Chardan Capital Markets LLC |
| Maximum shares of common stock | 160,000,000 | Potentially issued to Chardan Capital Markets LLC under the Purchase Agreement |
| Total Commitment Fee | $1.0M | Payable to Chardan Capital Markets LLC for the committed equity facility |
| Documentation Fee | $25,000 | Paid to Chardan Capital Markets LLC for the Purchase Agreement preparation |
| Date of Business Combination Agreement | July 11, 2025 | Initial agreement date for the merger with Sonnet and Rorschach |
| Date of Business Combination Agreement Amendment | September 22, 2025 | Amendment date for the merger with Sonnet and Rorschach |
| Bridge Financing | $2.0M | Sale of convertible notes by Sonnet BioTherapeutics Holdings, Inc. on June 30, 2025 |
| Bridge Financing Warrants | 865,052 | Shares of Company Common Stock convertible into 173,010 shares of Pubco Common Stock at closing |
| Closing PIPE shares of Company Common Stock | 243,787,992 | Issued at $1.25 per share, converting to 48,757,597 shares of Pubco Common Stock |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Hyperliquid Strategies Inc (PURR)?
Hyperliquid Strategies Inc has 4 recent SEC filings from Oct 2025 to May 2026, including 1 424B3, 1 10-Q, 1 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PURR filings?
Across 4 filings, the sentiment breakdown is: 2 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Hyperliquid Strategies Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Hyperliquid Strategies Inc (PURR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Hyperliquid Strategies Inc?
Key financial highlights from Hyperliquid Strategies Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PURR?
The investment thesis for PURR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Hyperliquid Strategies Inc?
Key executives identified across Hyperliquid Strategies Inc's filings include David Schamis, Alan I. Annex, Esq., Jason T. Simon, Esq..
What are the main risk factors for Hyperliquid Strategies Inc stock?
Of PURR's 3 assessed filings, 2 were flagged high-risk, 1 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Hyperliquid Strategies Inc?
Forward guidance and predictions for Hyperliquid Strategies Inc are extracted from SEC filings as they are enriched.